**4. Conclusions**

The intravenous iron formulation are safe for use in the perioperative period. The use of one formula to the detriment of others is not standardized yet, the selection criteria especially being the patient profile, the prescriber's experience, the drug availability, and the time left until the surgery. The new drugs are available in a single, higher dose that allow rapid correction of anemia, granting early surgery, and reducing the number of hospital visits. The correction of iron deficiency in surgical patients is vital for overall outcome, being related with a reduced need of allogeneic blood transfusion and all associated complications, faster recovery after surgery, low rate of infections, reduced length of stay in the hospital, reduced rate of complications, and a lower cost.

**Author Contributions:** M.T, ., T.P.N., and A.N. contributed to data collection, analysis and interpretation, as well as to the writing of the article. I.L. and I.M.G. contributed to the critical revision. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
